A Phase 2b Open-label Study of Selinexor (KPT-330) in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) SADAL Study: Selinexor against Diffuse Aggressive Lymphoma

Project: Research

Project Description

NMA HREC Reference Number: HREC/17/RAH/536
NMA SSA Reference Number: SSA/18/MonH/356
Monash Health Ref: RES-18-0000-238X
StatusActive
Effective start/end date12/06/1911/06/24

Keywords

  • clinical trial
  • lymphoma
  • treatment efficacy